SAB Biotherapeutics posts Q3 net income of $45.4 million
SAB Biotherapeutics Inc. reported a Q3 net income of $45.4 million in 2025, reversing a net loss of $10.3 million in 2024. For the nine months ended September 30, 2025, net income was $30.1 million, up from a net loss of $22.7 million in the prior year. Cash and equivalents totaled $161.5 million as of September 30, 2025. R&D expenses increased to $9.0 million for the quarter. The company initiated a Phase 2b trial for SAB-142 in autoimmune type 1 diabetes.
SAB Biotherapeutics Inc. reported net income of $45.4 million for the third quarter of 2025, compared to a net loss of $10.3 million for the same period in 2024. For the nine months ended September 30, 2025, the company recorded net income of $30.1 million, up from a net loss of $22.7 million in the prior year period. Cash, cash equivalents, and available-for-sale securities totaled $161.5 million as of September 30, 2025, compared to $20.8 million as of December 31, 2024. Research and development expenses were $9.0 million for the quarter, up from $7.8 million in the previous year’s quarter, and $23.6 million for the nine months, compared to $22.6 million in the prior year. During the period, SAB Biotherapeutics initiated the registrational Phase 2b SAFEGUARD trial of SAB-142 for new-onset, Stage 3 autoimmune type 1 diabetes, with multiple trial sites activated and the first patient expected to be dosed by year-end. The company presented additional Phase 1 data for SAB-142 at EASD and ISPAD conferences. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SAB Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9575638-en) on November 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
